Articles MINT: opportunities in 'frontier' markets? The prospects for pharma in the MINT emerging countries of Mexico, Indonesia, Nigeria and Turkey.
Views & Analysis New frontiers in pharma: is ‘MINT’ the next ‘BRIC’? MINT countries: what the opportunities may be for pharma and healthcare.
News Uplizna is first drug FDA-cleared for rare disease IgG4-RD Amgen has bagged a second indication for its B cell-depleting therapy Uplizna after the FDA cleared it for rare inflammatory disease IgG4-RD.
Sales & Marketing Sponsored Health Trends 2025: Reimagining What's Possible Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possibl
